# Amgen Inc (AMGN) stock analysis and sentiment

Canonical page: https://synoptiv.com/stock/AMGN
Methodology: https://synoptiv.com/methodology
Author: Synoptiv Research Engine

Last analyzed: Aug 16, 2026

Amgen Inc (AMGN) last closed at $415.21, near the top of its 52-week range of $269.77–$421.79. Composite market sentiment across 1 analysis is neutral (+12 on a −100 to +100 scale), as of Aug 16, 2026.

## What the data says

Amgen closed at $415.21, sitting near the upper edge of a 52-week band that runs from $269.77 to $421.79. The stock is within about 2% of its high and roughly 54% above its low, so the past year has carried it across a wide span rather than holding it in a narrow channel — most of that distance has been covered in one direction.

The market values the business at roughly $225 billion, or about 25.8 times trailing earnings and 17.1 times forward estimates. That gap between the two multiples reflects expectations of higher earnings ahead, which sits alongside reported revenue growth of 9.5% and a profit margin near 23%. Price to book stands at 19.2, a figure shaped in large part by the balance sheet structure of a company that carries substantial intangible assets and debt from acquisitions. The dividend yield is 2.43%, and a beta of 0.41 means the shares have historically moved less than half as much as the broader market on a given day — a pattern more typical of large, established pharmaceutical names than of growth biotech.

Recent coverage is mostly sector-level rather than company-specific. Much of the flow consists of healthcare ETF comparisons — XLV against BBH, IBBQ, VHT and PBE — plus competitor stories on obesity drugs from Pfizer, Novo Nordisk and Eli Lilly, and head-to-head pieces on Abbott and Johnson & Johnson, none of which mention Amgen directly. The one item naming the company is an August 5 report that a law firm opened a class action investigation into a data breach involving exposure of patient health information.

## About Amgen Inc

Amgen Inc. is a biotechnology company that discovers, develops, manufactures, and markets human therapeutics worldwide. Its portfolio spans inflammation and immunology, bone health, cardiovascular disease, oncology, hematology, and nephrology, and includes Enbrel and Otezla in inflammatory conditions; Prolia and EVENITY in osteoporosis; XGEVA for skeletal-related events in patients with advanced cancer; Repatha for lowering cardiovascular risk; and BLINCYTO, KYPROLIS, Vectibix, and LUMAKRAS in oncology. Other marketed products include Nplate, Aranesp, TEPEZZA, KRYSTEXXA, TEZSPIRE, UPLIZNA, AIMOVIG, and Neulasta, along with a line of biosimilars such as MVASI, AMJEVITA, and WEZLANA.

The company sells primarily to healthcare providers — physicians and their clinics, dialysis centers, hospitals, and pharmacies — distributing through pharmaceutical wholesalers. It also develops and commercializes several products through collaborations, including TEZSPIRE with AstraZeneca and EVENITY with UCB. Amgen was incorporated in 1980 and is headquartered in Thousand Oaks, California.

## Company profile

- Symbol: AMGN
- Exchange: NASDAQ
- Security type: Stock
- Sector: Healthcare
- Industry: Drug Manufacturers - General
- Composite sentiment: neutral (12 on a -100 to +100 scale)

## Key statistics

| Metric | Value |
| --- | ---: |
| Market capitalization | $224.63B |
| Enterprise value | $267.79B |
| Trailing P/E | 25.77 |
| Forward P/E | 17.1 |
| Price to book | 19.2 |
| Price to sales | 5.9 |
| Dividend yield | 2.43% |
| Beta | 0.41 |
| Net margin | 22.95% |
| Revenue growth | 9.50% |
| Earnings growth | 64.90% |
| 52-week high | $421.79 |
| 52-week low | $269.77 |
| Average volume | 2.7M |

## Related stocks

- 950160.KQ
- 950220.KQ
- [ABBV](https://synoptiv.com/stock/ABBV)
- 950220.KQ
- [GILD](https://synoptiv.com/stock/GILD)
- [VRTX](https://synoptiv.com/stock/VRTX)
- [REGN](https://synoptiv.com/stock/REGN)
- 950200.KQ
- [NTRA](https://synoptiv.com/stock/NTRA)
- [RVMD](https://synoptiv.com/stock/RVMD)
- [BIIB](https://synoptiv.com/stock/BIIB)

## Recent news

- [5 Safe High-Yield Stocks Boomers Should Own in August](https://247wallst.com/investing/2026/08/15/5-safe-high-yield-stocks-boomers-should-own-in-august/) — Aug 15, 2026
- [How To Invest $100,000 In A Retiree's SWAN Income Portfolio](https://seekingalpha.com/article/4934894-how-to-invest-100000-retiree-swan-income-portfolio) — Aug 15, 2026
- [GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk)](https://www.fool.com/investing/2026/08/14/glp-1-demand-is-soaring-2-stocks-that-could-benefi/) — Aug 14, 2026
- [What's going on in today's session: dow jones movers](https://www.chartmill.com/news/SHW/Chartmill-53622-Whats-going-on-in-todays-session-dow-jones-movers) — Aug 14, 2026
- [Dividend Champion, Contender, And Challenger Highlights: Week August 16](https://seekingalpha.com/article/4936944-dividend-champion-contender-and-challenger-highlights-week-august-16) — Aug 14, 2026
- [BofA biotech scorecard: Two buys and odd one out](https://www.thestreet.com/investing/stocks/bofa-biotech-stock-ratings-amgen-gilead-vertex) — Aug 14, 2026
- [Which dow jones stocks are moving on Friday?](https://www.chartmill.com/news/SHW/Chartmill-53616-Which-dow-jones-stocks-are-moving-on-Friday) — Aug 14, 2026
- [9 Health Care Stocks Whale Activity In Today’s Session](https://www.benzinga.com/markets/options/26/08/61220517/9-health-care-stocks-whale-activity-today-s-session) — Aug 14, 2026
- [Amgen (AMGN) Stock Looks Undervalued With A 37% Fair Value Gap](https://finance.yahoo.com/markets/stocks/articles/amgen-amgn-stock-looks-undervalued-120946360.html) — Aug 14, 2026
- [Amgen (AMGN) Opens New Science And Innovation Center In Hyderabad](https://finance.yahoo.com/healthcare/articles/amgen-amgn-opens-science-innovation-111231819.html) — Aug 14, 2026

## Frequently asked questions

### What is the current market sentiment for AMGN?

As of Aug 16, 2026, Amgen Inc (AMGN) carries neutral (+12 on a −100 to +100 scale) composite sentiment. The score fuses recent news tone, analyst recommendations, technical posture, insider and congressional activity, and market attention into a single figure. The full breakdown of each component is in the report.

### How has AMGN stock been performing?

Amgen Inc last closed at $415.21, near the top of its 52-week range of $269.77–$421.79.

### What is AMGN's market cap and valuation?

Amgen Inc has a market capitalization of about $224.63B, a trailing P/E of 25.8, a dividend yield of 2.43%.

### What sector is AMGN in, and who are its competitors?

Amgen Inc operates in the Healthcare sector, specifically Drug Manufacturers - General. Comparable companies include 950160.KQ, 950220.KQ, ABBV, 950220.KQ, GILD.

### Where can I find a full analysis of AMGN?

The full AMGN report covers the bull and bear cases, technical signals with entry, stop and target levels, complete financial statements, earnings history, insider and congressional trades, and the conditions that would invalidate the thesis. It requires a free account.

## Important information

This page is generated from public market and company information. Data can be delayed, incomplete, or wrong. It is research and analysis, not financial advice.

- [Methodology](https://synoptiv.com/methodology)
- [Disclosures](https://synoptiv.com/disclosures)
- [Full report](https://synoptiv.com/stock/AMGN/v/1) (account and access required)